• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>中国医学科学杂志（英文版） >Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy
【24h】

Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy

机译：近距离放疗结合外放疗和激素治疗治疗T3a前列腺癌的预后不良的结果

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Objective To evaluate the outcomes of T3a prostate cancer with unfavorable prognostic factors treated with permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy. Methods From January 2003 to December 2008, 38 patients classified as T3a prostate cancer with unfavorable prognostic factors were treated with trimodality therapy (brachytherapy + external radiotherapy+ hormone therapy). The prescription dose of brachytherapy and external radiotherapy were 110 Gy and 45 Gy, respectively. The duration of hormone therapy was 2-3 years. The endpoints of this study included biochemical failure-free survival (BFFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS). Survival curves were calculated using the Kaplan-Meier method. The Log-rank test was used to identify the prognostic predictors for univariate analysis. Results The median follow-up was 71 months. The serum pre-treatment prostate-specific antigen (PSA) level ranged from 10.0 to 99.8 ng/ml (mean 56.3 ng/ml), the Gleason score ranged from 5 to 9 (median 8), and the percentage of positive biopsy cores ranged from 10% to 100% (mean 65%). The 5-year BFFS, DMFS, CSS, and OS rates were 44%, 69%, 82%, and 76%, respectively. All biochemical failures occurred within 40 months. The percentage of positive biopsy cores was significantly correlated with BFFS, DMFS, and OS (all P=0.000), and the Gleason score with DMFS (P=0.000) and OS (P=0.001). Conclusions T3a prostate cancer with unfavorable prognostic factors presents not so optimistic outcome. Hormone therapy should be applied to prolong the biochemical progression-free or metastasis-free survival. The percentage of positive biopsy cores and the Gleason score are significant prognostic factors.
机译：目的评价永久性间质近距离放射治疗结合外放疗和激素治疗对T3a型前列腺癌的预后不良的预后。方法2003年1月至2008年12月，采用三联疗法（近距离放射疗法+外部放射疗法+激素疗法）治疗38例预后不良的T3a型前列腺癌患者。近距离放射疗法和外部放射疗法的处方剂量分别为110 Gy和45 Gy。激素治疗的持续时间为2-3年。这项研究的终点包括无生化失败生存率（BFFS），无远处转移生存率（DMFS），癌症特异性生存率（CSS）和总体生存率（OS）。使用Kaplan-Meier方法计算存活曲线。 Log-rank检验用于确定单因素分析的预后指标。结果中位随访时间为71个月。血清治疗前前列腺特异性抗原（PSA）的水平范围为10.0至99.8 ng / ml（平均56.3 ng / ml），Gleason评分范围为5至9（中位数8），阳性活检核心的百分比范围为从10％到100％（平均65％）。 5年的BFFS，DMFS，CSS和OS率分别为44％，69％，82％和76％。所有生化失败均发生在40个月内。阳性活检核心的百分比与BFFS，DMFS和OS（所有P = 0.000）显着相关，而Gleason评分与DMFS（P = 0.000）和OS（P = 0.001）显着相关。结论T3a前列腺癌预后不良，预后不良。应应用激素疗法以延长无生化进展或无转移的生存期。活检核心阳性的百分比和格里森评分是重要的预后因素。

著录项

  • 来源
    《中国医学科学杂志（英文版）》 |2015年第3期|143-149|共7页
  • 作者

    Zhi-peng Mai; Wei-gang Yan; Han-zhong Li; Yi Zhou; Zhi-en Zhou;

  • 作者单位

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号